Effects of alendronate on bone formation and osteoclastic resorption after implantation of beta-tricalcium phosphate

Journal of Biomedical Materials Research - Part A

Volumn 93, Issue 2, 2010, Pages 469-474

  Tanaka, Takaaki ^a,b   Saito, Mitsuru ^b   Chazono, Masaaki ^b   Kumagae, Yoshio ^a   Kikuchi, Takahiro ^b   Kitasato, Seiichiro ^b   Marumo, Keishi ^b  

^a National Hospital Organization Utsunomiya National Hospital   (Japan)

^b JIKEI UNIVERSITY SCHOOL OF MEDICINE   (Japan)

Author keywords

Bisphosphonate; Bone formation; Osteoblast; Osteoclast; Tricalcium phosphate

Indexed keywords

ALENDRONATE; ALN; BETA TRICALCIUM PHOSPHATE; BISPHOSPHONATES; BONE DEFECT; BONE FORMATION; CONCENTRATION OF; DOSE-DEPENDENT MANNER; FEMORAL CONDYLES; OSTEOCLAST FORMATION; TARTRATE-RESISTANT ACID PHOSPHATASE; TRI-CALCIUM PHOSPHATES;

BIOMATERIALS; OSTEOBLASTS; TRANSMISSION CONTROL PROTOCOL;

BONE;

ACID PHOSPHATASE TARTRATE RESISTANT ISOENZYME; ALENDRONIC ACID; CALCIUM PHOSPHATE;

ANIMAL EXPERIMENT; ANIMAL TISSUE; ARTICLE; BONE PROSTHESIS; CELL COUNT; CONCENTRATION RESPONSE; CONTROLLED STUDY; DRUG EFFECT; EXPERIMENTAL RABBIT; FEMUR CONDYLE; NONHUMAN; OSSIFICATION; OSTEOCLAST; OSTEOLYSIS; POROSITY; PROSTHESIS MATERIAL;

ALENDRONATE; ANIMALS; BIOCOMPATIBLE MATERIALS; BONE AND BONES; BONE DENSITY CONSERVATION AGENTS; BONE RESORPTION; CALCIUM PHOSPHATES; DOSE-RESPONSE RELATIONSHIP, DRUG; IMPLANTS, EXPERIMENTAL; OSTEOCLASTS; OSTEOGENESIS; RABBITS;

EID: 77950249567     PISSN: 15493296     EISSN: 15524965     Source Type: Journal    
DOI: 10.1002/jbm.a.32560     Document Type: Article

References (22)

1. Luckman SP, Hughes DE, Coxon FP, Russell RGG, Rogers MJ. Nitrogen-containing bisphosphonates inhibit the mevalonate pathway and prevent post-translational prenylation of GTP-binding proteins, including Ras. J Bone Miner Res 1988;13:581-589.
2. Venesmaa PK, Kroeger HP, Miettinen HJ, Jurvelin JS, Suomalainen OT, Alhav EM. Alendronate reduces periprosthetic bone loss after uncemented primary total hip arthroplasty: A prospective randomized study. J Bone Miner Res 2001;16:2126-2131.
3. Moroni A, Faldini C, Hoang-Kim A, Pegreffi F, Giannini S. Alendronate improves screw fixation in osteoporotic bone. J Bone Joint Surg Am 2007;89:96-101.
4. Omi H, Kusumi T, Kijima H, Toh S. Locally administered low-dose alendronate increases bone mineral density during distraction osteogenesis in a rabbit model. J Bone Joint Surg Br 2007;89:984-988.
5. Kitsugi T, Yamamoto T, Nakamura T, Kotani S, Kokubo T, Takeuchi H. Four calcium phosphate ceramics as bone substitutes for non-weight bearing. Biomaterials 1993;14:216-224.
6. Hoogendoorn HA, Renooji W, Akkermans LMA, Visser DDS, Wittebol P. Long-term study of large ceramic implants in dog femora. Clin Orthop 1984;187:281-288.
7. Chazono M, Tanaka T, Komaki H, Fujii K. Bone formation and bioresorption after implantation of β-tricalcium phosphate granules-hyaluronate complex in rabbit bone defects. J Biomed Mater Res 2004;15:542-549.
8. Tanaka T, Chazono M, Komaki H. Clinical application of β-tricalcium phosphate in human bone defects. Jikeikai Med J 2006;53:23-31.
9. Komaki H, Tanaka T, Chazono M, Kikuchi T. Repair of segmental bone defects in rabbit tibiae using a complex of β-tricalcium phosphate, type I collagen, and fibroblast growth factor-2. Biomaterials 2006;27:5118-5126.
10. Tanaka T, Kumagae Y, Saito M, Chazono M, Komaki H, Kikuchi T, Kitasato S, Marumo K. Bone formation and resorption in patients after implantation of β-tricalcium phosphate blocks with 60% and 75% porosity in opening wedge high tibial osteotomy. J Biomed Mater Res B Appl Biomater 2008;86:453-459.
11. Peter B, Pioletti DP, Laib S, Bujoli B, Pilet P, Janvier P, Guicheux J, Zambelli PY, Bouler JM, Gauthier O. Calcium phosphate drug delivery system: Influence of local zoledronate release on bone implant osteointegration. Bone 2005;36:52-60.
12. Faucheux C, Verron E, Soueidan A, Josse S, Arshad MD, Janvier P, Pilet P, Bouler JM, Bujoli B, Guicheux J. Controlled release of bisphosphonate from a calcium phosphate biomaterial inhibits osteoclastic resorption in vitro. J Biomed Mater Res A 2009;89:46-56.
13. Boanini E, Torricelli P, Gazzano M, Giardino R, Bigi A. Alendronate-hydroxyapatite nanocomposites and their interaction with osteoclasts and osteoblast-like cells. Biomaterials 2008;29:790-796.
14. Azuma Y, Sato H, Oue Y, Okabe K, Ohta T, Tsuchimoto M, Kiyoki M. Alendronate distributed on bone surfaces inhibits osteoclastic bone resorption in vitro and in experimental hypercalcemia models. Bone 1995;16:235-245.
15. Giuliani N, Pedrazzoni M, Negri G, Passeri G, Impicciatore M, Girasole G. Bisphosphonates stimulate formation of osteoblast precursors and mineralized nodules in murine and human bone marrow cultures in vitro and promote early osteoblastogenesis in young and aged mice in vivo. Bone 1998;22:455-461.
16. Im GI, Qureshi SA, Kenney J, Rubash HE, Shanbhag AS. Osteoblast proliferation and maturation by bisphosphonates. Biomaterials 2004;25:4105-4115.
17. von Knoch F, Jaquiery C, Kowalsky M, Achaeren S, Alabre C, Martin I, Rubash HE, Shanbhag AS. Effects of bisphosphonates on proliferation and osteoblast differentiation of human bone marrow stromal cells. Biomaterials 2005;26:6941-6949.
18. Duque G, Rivas D. Alendronate has an anabolic effect on bone through the differentiation of mesenchymal stem cells. J Bone Miner Res 2007;22:1603-1611.
19. Idris AI, Rojas J, Greig IR, van't Hof RJ, Ralston SH. Aminobisphosphonates cause osteoblast apoptosis and inhibit bone nodule formation in vitro. Calcif Tissue Int 2008;82:191-201.
20. Peter CP, Cook WO, Nunamaker DM, Provost MT, Seedor JG, Rodan GA. Effect of alendronate on fracture healing and bone remodeling in dogs. J Orthop Res 1996;14:74-79.
21. Lyles KW, Colon-Emeric CS, Magaziner JS, Adachi JD, Pieper CF, Mautalen C, Hyldstrup L, Recknor C, Nordsletten L, Moore KA, Lavecchia C, Zhang J, Mesenbrink P, Hodgson PK, Abrams K, Orloff JJ, Horowitz Z, Eriksen EF, Boonen S. Zoledronic acid and clinical fractures and mortality after hip fracture. N Engl J Med 2007;357:1799-1809.
22. Lenart BA, Lorich DG, Lane JM. Atypical fractures of the femoral diaphysis in postmenopausal woman taking alendronate. N Engl J Med 2008;358:1304-1305.